Actuate Therapeutics Inc (ACTU) Stock Analysis & Investment Frameworks
Actuate Therapeutics Inc (ACTU) stock analysis on Invetso. Review Actuate Therapeutics Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Actuate Therapeutics Inc Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Actuate Therapeutics Inc Key Financial Metrics
- Market Cap: $11.41M
- Revenue: $N/A
- ROE: -346.18%
- ROIC: -1489.99%
- Dividend Yield: N/A
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Actuate Therapeutics Inc Investment Frameworks
Invetso analyzes Actuate Therapeutics Inc (ACTU) across the following frameworks:
- Actuate Therapeutics Inc 10Y Growth Potential
- Actuate Therapeutics Inc Scenario Analysis
- Actuate Therapeutics Inc Risks & Opportunities
- Actuate Therapeutics Inc Economic Moat
- Actuate Therapeutics Inc Business Model
- Actuate Therapeutics Inc Management
- Actuate Therapeutics Inc SWOT Analysis
- Actuate Therapeutics Inc Porter's 5 Forces
- Actuate Therapeutics Inc PESTLE Analysis
- Actuate Therapeutics Inc ESG Analysis